We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases.
- Authors
Mavligit, Giora M.; Zukixvski, Alexander A.; Charnsangavej, Chuslip; Carrasco, C. Humberto; Wallace, Sidney; Gutterman, Jordan U.; Mavligit, G M; Zukiwski, A A; Charnsangavej, C; Carrasco, C H; Wallace, S; Gutterman, J U
- Abstract
Twenty-two chemotherapy-resistant patients with liver metastases received 46 courses of recombinant human tumor necrosis factor (rhTNF) administered by 5-day continuous infusion through percutaneously inserted hepatic arterial catheters. The maximum tolerated daily dose of rhTNF was 150 micrograms/m2. This is six times the maximum tolerated daily dose of rhTNF that could be given systemically (intravenous) on the same schedule. The dose-limiting toxicity resulted in severe, although transient, hypophosphatemia (less than 1.0 mg/dl) associated with myocardial dysfunction. Objective tumor response (partial tumor response or greater) was observed in 2 of 14 patients (14%) with colorectal cancer and lasted as long as 3 months. Three additional minor responses occurred among these patients with colorectal cancer. Plasma carcinoembryonic antigen levels also decreased significantly (greater than 25%) in 7 of the 14 (50%) patients with colorectal cancer. Regional biologic therapy with rhTNF as a sole modality has definite antitumor activity in colorectal cancer metastatic to the liver and warrants additional study in previously untreated patients.
- Subjects
DRUG resistance; HEPATIC artery; LIVER tumors; RECOMBINANT proteins; TUMOR necrosis factors; DISEASE remission; INTRA-arterial infusions
- Publication
Cancer (0008543X), 1992, Vol 69, Issue 2, p557
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19920115)69:2<557::AID-CNCR2820690246>3.0.CO;2-Q